Isatuximab-irfc (Sarclisa®) in Patients with Relapsed/Refractory Multiple Myeloma

The treatment and management of oncology patients is continually changing and evolving. The growing complexity creates a need for healthcare professionals to have a quick resource to turn to for drug therapy management information. The medically integrated team is in a unique position to ensure appropriate treatment, increase compliance, and maximize outcomes. Positive Quality Interventions (PQIs), an NCODA Quality Standard, are designed to operationalize and standardize those practices to achieve these positive clinical outcomes. This resource consists of peer-reviewed clinical guidance document for members of the oncology healthcare team. They provide quality standards, best practices, and foster better outcomes for oncology patients in a succinct, easy to digest format. This PQI in Action is a follow up to the the Isatuximab-irfc (SARCLISA®) PQI. We will dive in depth into how Massachusetts General Cancer Center and Yale New Haven Health – Smilow Cancer Hospital incorporate PQIs into their practice settings, and will discuss how utilizing the Isatuximab-irfc (SARCLISA®) In Patients with Relapsed/Refractory Multiple Myeloma PQI elevates patient care.